CA-DENODO
29.2.2024 08:31:33 CET | Business Wire | Press release
Denodo, a leader in data management, today announced that Forrester Research, Inc. has positioned Denodo as a Leader in The Forrester Wave™: Enterprise Data Fabric, Q1 2024. According to the report, “Denodo is a great fit for customers focusing on an enterprise-wide data fabric strategy to support real-time analytics, customer 360, data engineering, data science, IoT analytics, operational insights, and predictive analytics use cases.” Denodo and 14 other vendors were evaluated across 26 criteria, including current offering, strategy, and market presence.
The complete and complimentary report, published on February 28, is available here.
The Wave revealed that while data fabric traditionally focused on read-only analytical use cases, there is a notable shift towards transactional fabric, with bidirectional read-and-write capabilities to support modern applications such as microservices and real-time customer experience. Today, enterprises are leveraging data fabric to accelerate new and emerging business cases such as customer experience, data science, IoT insights, global transactions, fraud prevention, business 360, and real-time insights.
Forrester VP, Principal Analyst and author of the report, Noel Yuhanna wrote, “Denodo Technologies delivers a world-class data fabric solution. [They have] been a longtime player in data virtualization and now support enterprise data fabric with next-generation data management capabilities. Denodo’s superior data fabric roadmap suggests a focus on advanced data integration, GenAI/LLM, vector search, faster data ingestion, automation, and self-service capabilities.”
Denodo received the highest scores possible in eight criteria, including deployment options, data access and search, data delivery, data processing and persistence, data transformation and lineage, and data integration. The report noted that reference customers like Denodo’s flexible platform, technical support, support for data mesh, data integration, and roadmap.
“This Forrester Research recognition validates, in our opinion, the value of our enterprise data fabric deployments and cloud service. Our customers use the Denodo Platform to establish a common data foundation across the IT corporate infrastructure that enables data products to be created at the speed – and with the agility – required by business users,” said Angel Viña, CEO and Founder at Denodo. “Through this Forrester report, our customers are telling us why Denodo is at the forefront of data management innovation: We simplify data integration through data virtualization technology, which eliminates unnecessary data movement; we accelerate data solutions because we create data ecosystems with true, unified semantics; we speed up time-to-production because we make it faster to access the data in distributed systems; we add self-service capabilities; and we enable new Generative AI applications by helping to create contextualized LLM models that learn from patterns in their own business data.”
With some of the best-in-class and latest innovations, the Denodo Platform:
- Provides IT organizations the flexibility to evolve their data strategies, migrate to the cloud or logically unify data assets without disrupting the business.
- Accelerates data provisioning without requiring costly replication of the data.
- Supports consistent security and governance across multiple systems.
- Enables self-service by giving business users the ability to discover, access and prepare data on their own.
Please Tweet: https://ctt.ac/di1R4
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228251918/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release
Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release
– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
